The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
Endocrinology and Metabolism · 29.02.2024 · 39 (1) · 12-22
DOI: 10.3803/enm.2024.1942 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 29.02.2024. Verfasst von Agnieszka Jakubowska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science Foundation Ireland, Health Research Board, Amarin.
Abstract (Originalsprache)
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic landscape. The successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, followed by the synergistic combined effect of glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists achieved remarkable weight loss and glycemic control in those with the diseases of obesity and type 2 diabetes. The multiple cardiometabolic benefits include improving glycemic control, lipid profiles, blood pressure, inflammation, and hepatic steatosis. The 2023 phase 2 double-blind, randomized controlled trial evaluating a GLP-1/GIP/glucagon receptor triagonist (retatrutide) in patients with the disease of obesity reported 24.2% weight loss at 48 weeks with 12 mg retatrutide. This review evaluates the current available evidence for GLP-1 receptor agonists, dual GLP-1/GIP receptor co-agonists with a focus on GLP-1/GIP/glucagon receptor triagonists and discusses the potential future benefits and research directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Borthwick Diabetes Research Centre, Lister Hospital, Stevenage, UK.
- Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
Förderung
- Science Foundation Ireland
- Health Research Board
- Amarin
- Amgen
- Astra Zeneca
- Boehringer Ingleheim
- Daiichi-Sankyo
- Eli Lilly Japan
Zitieren
APA
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024). The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and Metabolism, 39(1), 12-22. https://doi.org/10.3803/enm.2024.1942
Vancouver
Jakubowska A, Roux CWL, Viljoen A. The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinology and Metabolism. 2024;39(1):12-22. doi:10.3803/enm.2024.1942
BibTeX
@article{Jakubowska2024,
author = {Jakubowska, Agnieszka and Roux, Carel W le and Viljoen, Adie},
title = {The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update},
journal = {Endocrinology and Metabolism},
year = {2024},
volume = {39},
number = {1},
pages = {12--22},
doi = {10.3803/enm.2024.1942}
}
EUVIMED